473416-91-0

Usage

Uses

Used in Organic Synthesis:
BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO is used as a key intermediate in the synthesis of various organic compounds. Its unique structure, containing both bromine and fluorine atoms, allows for a wide range of chemical reactions, making it a valuable building block in the production of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO is used as a starting material for the synthesis of various drug molecules. Its presence in the molecular structure can impart specific properties, such as increased stability or improved bioavailability, which are crucial for the effectiveness of the final drug product.
Used in Agrochemical Industry:
BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO is also utilized in the agrochemical industry for the synthesis of active ingredients in pesticides and herbicides. Its unique chemical properties can contribute to the development of more effective and environmentally friendly agrochemical products.
Used in Specialty Chemicals:
BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO is employed as a raw material in the production of specialty chemicals, such as dyes, fragrances, and polymers. The incorporation of BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO into these products can enhance their performance characteristics, such as color intensity, scent longevity, or material properties.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 348-57-2 2,4-difluorobromobenzene 
• 28342-75-8 1,5-dibromo-2,4-difluorobenzene 

Downstream Products

• 633327-10-3 2,4-difluoro-5-formylbenzonitrile 
• 1585970-78-0 (R)-N-((S)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1585971-39-6 (R,E)-N-(1-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)ethylidene)-2-methylpropane-2-sulfinamide 
• 1616105-35-1 1-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)ethanone 
• 1616100-67-4 1-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)ethanol 
• 1616100-26-5 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,4-dimethylisoxazol-5-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-25-4 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616101-01-9 (4S,6R)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-22-1 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-10-7 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616099-61-6 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,4-dimethoxyphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-78-7 N-(((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,4-dimethyloxazol-5-yl)-4-hydroxybutan-2-yl)carbamothioyl)benzamide 
• 1616100-77-6 (1R,3S)-3-amino-3-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-1-(2,4-dimethyloxazol-5-yl)butan-1-ol 
• 1616100-76-5 (R)-N-((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,4-dimethyloxazol-5-yl)-4-hydroxybutan-2-yl)-2-methylpropane-2-sulfinamide 

Relevant academic research and scientific papers

4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS

The present invention covers 4-(3-amino-6-fluoro-1H-indazol-5-yl)-1,2,6-trimethyl-1,4- dihydropyridine-3,5-dicarbonitrile compounds of general formula (I) : in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases.

GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein R1, R2, R3, R4, R5, and R6 are independently hydrogen, C1-C6 alkyl or C1-C6 cycloalkyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group, wherein each Y and Z group can be optionally substituted with from 0-3 substituents selected from halogen, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, OH, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is either a bond or is -NHCO-; L and Z together can be absent; and m is 1, 2 or 3.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

BACE INHIBITORS

The present invention provides BACE inhibitors of Formula I: methods for their use, intermediates, and methods for their preparation.

PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates -(CO)h-(NRa)j-(CRb=CRc)k-Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X-Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).